Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Zoetis shares jump on beat-and-raise

Published 05/02/2024, 07:31 AM
ZTS
-

NEW YORK - Zoetis Inc . (NYSE:ZTS) reported a solid start to the year with first-quarter earnings and revenue that surpassed Wall Street's expectations, prompting a 4% surge in its stock price.

The company, a global leader in animal health, announced an adjusted diluted EPS of $1.38 for the first quarter of 2024, exceeding the analyst consensus by $0.03. Revenue also beat expectations, coming in at $2.2 billion against a forecasted $2.15 billion.

The company's revenue represented a 10% increase from the same quarter last year, with operational growth reaching 12%. Adjusted net income saw a 15% operational increase, reflecting robust financial health. Zoetis credited its performance to a 16% revenue growth in the U.S. and an 8% operational increase internationally.

The companion animal portfolio, which grew by an impressive 20% operationally, was particularly highlighted for its contribution, driven by strong sales in pet parasiticides, osteoarthritis pain, and dermatology products.

CEO Kristin Peck expressed pride in the company's first-quarter achievements, attributing the success to Zoetis' diverse portfolio and innovation in the animal health market. "We achieved 16% revenue growth in the U.S. and 8% operational revenue growth internationally," Peck stated, emphasizing the company's commitment to investing in future growth.

Looking forward, Zoetis has updated its full-year 2024 guidance, now expecting revenue to be between $9.050 billion and $9.200 billion, with an adjusted EPS forecast of $5.71 to $5.81. This guidance places the midpoint of the EPS range slightly below the consensus estimate of $5.78, while the revenue guidance brackets the consensus of $9.157 billion.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The company also anticipates an operational revenue growth of 8.5% to 10.5% and a 13% to 15% increase in adjusted net income for the full year.

Investors reacted positively to the earnings beat and the upward revision of the company's outlook, as reflected in the stock's 4% climb. The market's response underscores confidence in Zoetis' ability to maintain its growth trajectory and continue delivering shareholder value.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.